Skyepharma, Mundipharma deal

Skyepharma granted Mundipharma an option to license exclusive, worldwide rights to develop and commercialize SKP-2076 following feasibility work, which Skyepharma expects to complete in 2Q16.

If Mundipharma exercises its option, Skyepharma would provide chemistry, manufacturing and control services to Mundipharma to support development, which Mundipharma would fund. Skyepharma began the feasibility work in early 2015 and is expected to be ready to move into GMP pilot-scale manufacturing this year. ...